Effectiveness of Acupuncture in Cervical Dystonia

2010 ◽  
Vol 28 (2) ◽  
pp. 94-96 ◽  
Author(s):  
Ravindran Deepak ◽  
Hans Mathew ◽  
Mathew Koshy
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Cervical Dystonia ◽  
Muscle Tone ◽  
Muscle Spasm ◽  
Treatment Combination ◽  
First Case ◽  
Botulinum Toxin Injections

This case describes the successful addition of acupuncture to treat a patient with cervical dystonia previously managed with Botox (botulinum toxin) injections. This resulted in reduced pain and muscle spasm relief and to the authors’ knowledge is the first case to be reported using this treatment combination. The patient was diagnosed with the idiopathic variant of cervical dystonia and had been treated with regular Botox injections for almost a year and half. She was then referred for a course of acupuncture to manage pain and reduce excessive muscle tone. She had excellent benefit from the acupuncture and she continued to get top-ups of acupuncture every 8–10 weeks. Requirement for Botox injections had decreased thus reducing its long-term side effects.

scholarly journals Experiences on the administration of botulinum toxin in movement disorders

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Buket Tuğan Yıldız ◽  
Deniz Tuncel Berktaş
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Cervical Dystonia ◽  
Botulinum Toxin Injection ◽  
Wide Range ◽  
Generalized Dystonia ◽  
Duration Of Efficacy ◽  
Botulinum Toxin Treatment ◽  
Botulinum Toxin Injections ◽  
Made In

AbstractBackground and objectivesBotulinum toxin injection has been used for many years for various indications such as cervical dystonia, blepharospasm, oromandibular dystonia, hemifacial spasm in neurology. Botulinum toxin injections have been made in our clinic for about ten years. We want to report our experiences about botulinum toxin treatment in neurologic disease.MethodsIn this study, the data of the patients receiving BoNT injection between January 2018 and December 2019 was retrospectively analyzed. Age, gender, botulinum toxin indications, and mean dose, duration of efficacy, side effects noted for each injection were recorded.ResultsThere were 122 patients who received botulinum toxin injections between January 2018 and December 2019. Of the 122 patients identified, 28 had cervical dystonia, 61 had HFS, 21 had blepharospasm, 4 had generalized dystonia, 1 had hemidystonia following thalamic bleeding, 1 had tardive dystonia, 4 had migraine, 1 had bruxism and 1 had both migraine and bruxism.ConclusionBoNT injection is a treatment that has been used for various indications in neurology for almost 40 years. Side effects are limited and temporary with appropriate injections. We also had a wide range of indication profiles and high numbers of patients to whom we administered the BoNT treatment.

scholarly journals Hereditary geniospasm in a mother and son treated with botulinum toxin injection: A case report

2021 ◽  
Vol 9 ◽  
pp. 2050313X2199359
Author(s):  
Clare Perkins ◽  
Wei Jia ◽  
James Rainsbury ◽  
Andrew Lux
Keyword(s):  
Case Report ◽  
Botulinum Toxin ◽  
Side Effects ◽  
Beta Blockers ◽  
Botulinum Toxin Injection ◽  
Treatment Options ◽  
Benign Disorder ◽  
The World ◽  
Botulinum Toxin Injections

Hereditary geniospasm is a rare and benign disorder that can cause distress and social embarrassment to patients. There are only a handful of possible treatment options available. Due to the rarity of the condition, practices differ across the world and the results are varied. These include beta-blockers, benzodiazepines and anti-epileptics. These treatments can have significant side-effects when used long term. However, botulinum toxin injections have been successfully used in a handful of cases. We report a successful botulinum treatment of hereditary geniospasm in a mother and son, with the injection protocols.

scholarly journals Constraint-Induced Movement Therapy After Injection of Botulinum Toxin Type A for a Patient With Chronic Stroke: One-Year Follow-up Case Report

2015 ◽  
Vol 95 (7) ◽  
pp. 1039-1045 ◽  
Author(s):  
Satoru Amano ◽  
Takashi Takebayashi ◽  
Keisuke Hanada ◽  
Atsushi Umeji ◽  
Kohei Marumoto ◽  
...  
Keyword(s):  
Case Report ◽  
Botulinum Toxin ◽  
Muscle Tone ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Movement Therapy ◽  
Chronic Stroke ◽  
Constraint Induced Movement Therapy ◽  
Arm Function

Background and Purpose Spasticity, an aspect of upper motor neuron syndrome, is a widespread problem in patients with stroke. To date, no study has reported the long-term (up to 1 year) outcomes of botulinum toxin (BTX) injection in combination with constraint-induced movement therapy in patients with chronic stroke. In this case report, the long-term (1 year) effects of the combination of BTX type A injection and constraint-induced movement therapy on spasticity and arm function in a patient with chronic stroke and arm paresis are described. Case Description The patient was a 66-year-old man who had had an infarction in the right posterior limb of the internal capsule 4 years before the intervention. At screening, the patient was not able to voluntarily extend his interphalangeal or metacarpophalangeal joints beyond the 10 degrees required for constraint-induced movement therapy. From 12 days after BTX type A injection, the patient received 5 hours of constraint-induced movement therapy for 10 weekdays. Outcomes All outcome measures (Modified Ashworth Scale, Fugl-Meyer Assessment, Action Research Arm Test, and amount of use scale of the Motor Activity Log) improved substantially over the 1-year period (before intervention to 1 year after intervention). Repeat BTX type A injections were not necessary because muscle tone and arm function did not worsen during the observation period. Discussion The improved arm function may have reflected improvements in volitional movements and coordination or speed of movements in the paretic arm as a result of a reduction in spasticity, a reduction of learned nonuse behaviors, or use-dependent plasticity after the combination of BTX type A injection and constraint-induced movement therapy. In addition, the possibility of an influence of the passage of time or the Hawthorne effect cannot be ruled out. If this approach proves useful in future controlled studies, it may reduce the rising medical costs of the treatment of stroke.

The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia

2014 ◽  
Vol 21 (12) ◽  
pp. 1486-e98 ◽  
Author(s):  
C. C. S. Delnooz ◽  
L. C. Veugen ◽  
J. W. Pasman ◽  
B. G. Lapatki ◽  
J. P. van Dijk ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Clinical Utility ◽  
Motor Endplate ◽  
Botulinum Toxin Injections

scholarly journals Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid

2017 ◽  
Vol 11 (2) ◽  
pp. 440-445 ◽  
Author(s):  
Jenny Sarah Schneider ◽  
Matteo Montani ◽  
Felix Stickel
Keyword(s):  
Liver Disease ◽  
Zoledronic Acid ◽  
Side Effects ◽  
Liver Injury ◽  
Drug Reactions ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
First Case ◽  
Alternative Drugs

Adverse drug reactions are among the most frequent side effects of synthetic and complementary alternative drugs and represent the premier causes of license revocations and acute liver failure. Drug-induced liver injury can resemble literally any other genuine liver disease and usually responds well to drug dechallenge. However, in some cases autoimmune-like hepatitis can evolve, requiring short- and sometimes long-term immunosuppression. Here, we present the hitherto first case of autoimmune-like hepatitis following treatment with zoledronic acid.

Botulinum toxin A and cervical dystonia: A long-term monocentric experience

2021 ◽  
Vol 429 ◽  
pp. 119548
Author(s):  
Luca Bosco ◽  
Carla Butera ◽  
Giacomo Sferruzza ◽  
Stefano Amadio ◽  
Roberta Guerriero ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Botulinum Toxin A ◽  
Toxin A

scholarly journals How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study

2019 ◽  
Vol 266 (12) ◽  
pp. 3038-3046 ◽  
Author(s):  
Carlo Colosimo ◽  
◽  
David Charles ◽  
Vijay P. Misra ◽  
Pascal Maisonobe ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Botulinum Toxin ◽  
Observational Study ◽  
Cervical Dystonia ◽  
Treatment Cycle ◽  
Symptom Control ◽  
Type A ◽  
Peak Effect ◽  
End Of Treatment

Abstract Background Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice. Methods This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle. Results Subject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of − 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years. Conclusions Despite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.

Sign in / Sign up

Export Citation Format

Share Document